Plain-English translation of NCT07160686 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help prevent blood clots in people with advanced lung cancer who are undergoing chemotherapy or radiation as outpatients. Blood clots are a serious and common complication for lung cancer patients receiving treatment, and this medication might reduce that risk. Right now, preventing blood clots in outpatient cancer patients is not standard practice, so researchers want to find out if this treatment is safe and effective.
People with lung cancer who are receiving chemotherapy or radiation have a much higher risk of developing dangerous blood clots, which can make their quality of life worse and even be life-threatening. Currently, there is no standard way to prevent these clots in outpatients, and the only option available (injections) is inconvenient, so researchers want to see if this medication — which is a simple tablet — can safely prevent blood clots.
You likely qualify if…
You likely don't qualify if…
You would take either the study medication or a placebo (dummy tablet) twice a day for 6 months while you continue your regular cancer treatment as an outpatient. Half of the participants will receive the real medication and half will receive the placebo — neither you nor the research team will know which one you're taking. The study will track whether you develop any blood clots and monitor your health and safety throughout the 6 months.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United Kingdom